Combination of procainamide and quinidine for better tolerance and additive effects for ventricular arrhythmias

Soo G. Kim, Steven W. Seiden, Jeffrey A. Matos, Lawrence E. Waspe, John Devens Fisher

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The efficacy and tolerance of quinidine and procainamide used individually and in combination were studied in 19 patients with frequent ventricular premature complexes (VPCs). During single-drug treatment, the maximum tolerated dose of quinidine without extracardiac dose-related side effects was 1.6 ± 0.21 g/day and that of procainamide was 4.1 ± 1.05 g/day. During combination therapy with smaller doses (p < 0.05) of quinidine (1.16 ± 0.26 g/day) and procainamide (2.80 ± 0.98 g/day), no patient had side effects. Before treatment, all patients had frequent (more than 60 per hour) VPCs and 17 had ventricular tachycardia on Holter monitoring. The frequency of VPCs was reduced to 22 ± 19% with quinidine, 47 ± 40% with procainamide and 9 ± 11% with combination therapy (p < 0.05, combination vs procainamide or quinidine alone). Individually, an effective regimen (more than 83% reduction of VPCs and abolition of ventricular tachycardia) was found in 5 patients (26%) receiving quinidine alone at maximal tolerated dose, in 4 (21%) receiving procainamide alone at maximal tolerated dose, and in 14 (74%) receiving combination therapy (p < 0.01 vs quinidine or procainamide). Thus, the antiarrhythmic effects of quinidine and procainamide are additive. When quinidine or procainamide is ineffective because dose-related extracardiac side effects limit the maximal tolerated dose, combination therapy in smaller and tolerable doses avoids side effects and is more effective than either drug alone at the maximal tolerated dose.

Original languageEnglish (US)
Pages (from-to)84-88
Number of pages5
JournalThe American Journal of Cardiology
Volume56
Issue number1
DOIs
StatePublished - Jul 1 1985

Fingerprint

Procainamide
Quinidine
Cardiac Arrhythmias
Maximum Tolerated Dose
Ventricular Premature Complexes
Ventricular Tachycardia
Therapeutics
Ambulatory Electrocardiography
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Combination of procainamide and quinidine for better tolerance and additive effects for ventricular arrhythmias. / Kim, Soo G.; Seiden, Steven W.; Matos, Jeffrey A.; Waspe, Lawrence E.; Fisher, John Devens.

In: The American Journal of Cardiology, Vol. 56, No. 1, 01.07.1985, p. 84-88.

Research output: Contribution to journalArticle

Kim, Soo G. ; Seiden, Steven W. ; Matos, Jeffrey A. ; Waspe, Lawrence E. ; Fisher, John Devens. / Combination of procainamide and quinidine for better tolerance and additive effects for ventricular arrhythmias. In: The American Journal of Cardiology. 1985 ; Vol. 56, No. 1. pp. 84-88.
@article{e0c922935aef45aeb206e4acc19e2e73,
title = "Combination of procainamide and quinidine for better tolerance and additive effects for ventricular arrhythmias",
abstract = "The efficacy and tolerance of quinidine and procainamide used individually and in combination were studied in 19 patients with frequent ventricular premature complexes (VPCs). During single-drug treatment, the maximum tolerated dose of quinidine without extracardiac dose-related side effects was 1.6 ± 0.21 g/day and that of procainamide was 4.1 ± 1.05 g/day. During combination therapy with smaller doses (p < 0.05) of quinidine (1.16 ± 0.26 g/day) and procainamide (2.80 ± 0.98 g/day), no patient had side effects. Before treatment, all patients had frequent (more than 60 per hour) VPCs and 17 had ventricular tachycardia on Holter monitoring. The frequency of VPCs was reduced to 22 ± 19{\%} with quinidine, 47 ± 40{\%} with procainamide and 9 ± 11{\%} with combination therapy (p < 0.05, combination vs procainamide or quinidine alone). Individually, an effective regimen (more than 83{\%} reduction of VPCs and abolition of ventricular tachycardia) was found in 5 patients (26{\%}) receiving quinidine alone at maximal tolerated dose, in 4 (21{\%}) receiving procainamide alone at maximal tolerated dose, and in 14 (74{\%}) receiving combination therapy (p < 0.01 vs quinidine or procainamide). Thus, the antiarrhythmic effects of quinidine and procainamide are additive. When quinidine or procainamide is ineffective because dose-related extracardiac side effects limit the maximal tolerated dose, combination therapy in smaller and tolerable doses avoids side effects and is more effective than either drug alone at the maximal tolerated dose.",
author = "Kim, {Soo G.} and Seiden, {Steven W.} and Matos, {Jeffrey A.} and Waspe, {Lawrence E.} and Fisher, {John Devens}",
year = "1985",
month = "7",
day = "1",
doi = "10.1016/0002-9149(85)90571-5",
language = "English (US)",
volume = "56",
pages = "84--88",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Combination of procainamide and quinidine for better tolerance and additive effects for ventricular arrhythmias

AU - Kim, Soo G.

AU - Seiden, Steven W.

AU - Matos, Jeffrey A.

AU - Waspe, Lawrence E.

AU - Fisher, John Devens

PY - 1985/7/1

Y1 - 1985/7/1

N2 - The efficacy and tolerance of quinidine and procainamide used individually and in combination were studied in 19 patients with frequent ventricular premature complexes (VPCs). During single-drug treatment, the maximum tolerated dose of quinidine without extracardiac dose-related side effects was 1.6 ± 0.21 g/day and that of procainamide was 4.1 ± 1.05 g/day. During combination therapy with smaller doses (p < 0.05) of quinidine (1.16 ± 0.26 g/day) and procainamide (2.80 ± 0.98 g/day), no patient had side effects. Before treatment, all patients had frequent (more than 60 per hour) VPCs and 17 had ventricular tachycardia on Holter monitoring. The frequency of VPCs was reduced to 22 ± 19% with quinidine, 47 ± 40% with procainamide and 9 ± 11% with combination therapy (p < 0.05, combination vs procainamide or quinidine alone). Individually, an effective regimen (more than 83% reduction of VPCs and abolition of ventricular tachycardia) was found in 5 patients (26%) receiving quinidine alone at maximal tolerated dose, in 4 (21%) receiving procainamide alone at maximal tolerated dose, and in 14 (74%) receiving combination therapy (p < 0.01 vs quinidine or procainamide). Thus, the antiarrhythmic effects of quinidine and procainamide are additive. When quinidine or procainamide is ineffective because dose-related extracardiac side effects limit the maximal tolerated dose, combination therapy in smaller and tolerable doses avoids side effects and is more effective than either drug alone at the maximal tolerated dose.

AB - The efficacy and tolerance of quinidine and procainamide used individually and in combination were studied in 19 patients with frequent ventricular premature complexes (VPCs). During single-drug treatment, the maximum tolerated dose of quinidine without extracardiac dose-related side effects was 1.6 ± 0.21 g/day and that of procainamide was 4.1 ± 1.05 g/day. During combination therapy with smaller doses (p < 0.05) of quinidine (1.16 ± 0.26 g/day) and procainamide (2.80 ± 0.98 g/day), no patient had side effects. Before treatment, all patients had frequent (more than 60 per hour) VPCs and 17 had ventricular tachycardia on Holter monitoring. The frequency of VPCs was reduced to 22 ± 19% with quinidine, 47 ± 40% with procainamide and 9 ± 11% with combination therapy (p < 0.05, combination vs procainamide or quinidine alone). Individually, an effective regimen (more than 83% reduction of VPCs and abolition of ventricular tachycardia) was found in 5 patients (26%) receiving quinidine alone at maximal tolerated dose, in 4 (21%) receiving procainamide alone at maximal tolerated dose, and in 14 (74%) receiving combination therapy (p < 0.01 vs quinidine or procainamide). Thus, the antiarrhythmic effects of quinidine and procainamide are additive. When quinidine or procainamide is ineffective because dose-related extracardiac side effects limit the maximal tolerated dose, combination therapy in smaller and tolerable doses avoids side effects and is more effective than either drug alone at the maximal tolerated dose.

UR - http://www.scopus.com/inward/record.url?scp=0021820001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021820001&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(85)90571-5

DO - 10.1016/0002-9149(85)90571-5

M3 - Article

C2 - 4014046

AN - SCOPUS:0021820001

VL - 56

SP - 84

EP - 88

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1

ER -